GSK claims Amgen v Sanofi decision “threatens” innovation
29-04-2021
Amgen antibody patents ‘too broad’, says Fed Circuit
16-02-2021
Sundry Photography / Shutterstock.com
Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen (filgrastim).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Pfizer, patent, cancer treatment
